J. Rick Turner – författare
Visar alla böcker från författaren J. Rick Turner. Handla med fri frakt och snabb leverans.
23 produkter
23 produkter
Inbunden, Engelska, 1992
1 671 kr
Skickas inom 10-15 vardagar
Demonstrating that the magnitude and pattern of cardiovascular response to stress varies markedly between individuals, this work discusses the mechanisms by which the cardiovascular system is mobilized during stress, the determinants of individual differences, and the pathophysiological processes by which responses to stress may lead to cardiovascular disease. Behavioral scientists from a variety of disciplines will find the work pertinent to their research.
Inbunden, Engelska, 1994
1 116 kr
Skickas inom 10-15 vardagar
This book is an articulate, concise, contemporary introduction to the study of important variables underlying cardiovascular reactivity. Its strength is in the combination of a scholarly but nonpedantic approach to cardiovascular psychophysiology and a solid understanding of be havioral medicine approaches to the study of hypertension. The topics covered are central to the study of relationships between behavior and cardiovascular reactivity; the list of suggested readings at the end of each chapter provides excellent guidance for more detailed study of specific issues. It has now been more than a dozen years since Plenum Press published Paul Obrist's seminal monograph Cardiovascular Psycho physiology. The volume had a major impact in relating cardiovascular regulation to behaving individuals and in developing thoughtful hy potheses concerning such factors as they might pertain to hypertension. The impact of that work extended across scientific disciplines as well as aross continents. At the time the Obrist book was published, a young psychologist, J. Rick Turner, was completing his Ph. D. thesis in psychol ogy at the University of Birmingham, England, on heart rate reactions to psychological challenge. After continued collaboration for the next several years with his former Ph. D. mentor, Douglas Carroll, Turner joined the Obrist laboratory at the University of North Carolina. Al though Obrist unfortunately died during Turner's tenure in the labora tory, collaboration continued with Kathleen Light and Andrew Sher wood. The enlightened legacy of the North Carolina laboratory can clearly be seen in this text.
Inbunden, Engelska, 1995
1 671 kr
Skickas inom 10-15 vardagar
Leading researchers examine how behavior genetics provides crucial insights into genetic and environmental influences in the development of biobehavioral disorders. These influences are illustrated by using the examples of cardiovascular disease, obesity and eating disorders, alcohol use and abuse, and smoking behavior. Contributors discuss the relevance of molecular genetic approaches and twin and family designs to the complex field of behavior medicine research.
Inbunden, Engelska, 2008
1 334 kr
Skickas inom 5-8 vardagar
The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug's cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug's life, from discovery and development through postmarketing research. This self-contained, reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, government officials, and students.
E-bok
PDF, Engelska, 20081 531 kr
Läs direkt efter köp
The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug''s cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug''s life, from discovery and development through postmarketing research. This self-contained, reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, government officials, and students.
Inbunden, Engelska, 2001
2 759 kr
Skickas inom 3-6 vardagar
Having trouble finding a book that shows you not only how to analyze data but also how to collect the data appropriately and fully interpret the analysis, too? Here's a new book that does all this in a particularly readable fashion. Turner and Thayer's text: Shows how to design an experiment in the best possible way to investigate the topic of interest Explains which associated analysis will best answer your research question Demonstrates how to conduct the analysis and then fully interpret the results in the context of your research question
Organized so that the reader moves from the simplest type of design to more complex ones, the authors introduce five different kinds of ANOVA techniques and explain which design/analysis is appropriate to answer specific questions. They show how to perform each analysis using only a calculator to provide the reader with a better "feel" for the analyses than simply seeing the mathematical answers on a computer print-out. The book concludes with tips for tests on ANOVA, and descriptions of how to use the knowledge gained from the text to determine the credibility of claims made and "statistics" presented in various types of reports.
Häftad, Engelska, 2001
1 777 kr
Skickas inom 3-6 vardagar
Having trouble finding a book that shows you not only how to analyze data but also how to collect the data appropriately and fully interpret the analysis, too? Here's a new book that does all this in a particularly readable fashion. Turner and Thayer's text: Shows how to design an experiment in the best possible way to investigate the topic of interest Explains which associated analysis will best answer your research question Demonstrates how to conduct the analysis and then fully interpret the results in the context of your research question
Organized so that the reader moves from the simplest type of design to more complex ones, the authors introduce five different kinds of ANOVA techniques and explain which design/analysis is appropriate to answer specific questions. They show how to perform each analysis using only a calculator to provide the reader with a better "feel" for the analyses than simply seeing the mathematical answers on a computer print-out. The book concludes with tips for tests on ANOVA, and descriptions of how to use the knowledge gained from the text to determine the credibility of claims made and "statistics" presented in various types of reports.
E-bok
Engelska, 201315 707 kr
Läs direkt efter köp
This encyclopedia advances the understanding of behavioral medicine principles and clinical applications among researchers and practitioners in medicine, psychology, public health, epidemiology, nursing, and social work. In addition, the encyclopedia provides useful synergies for sociologists, anthropologists, and undergraduates with some interest in the interface of human health and behavior.
Areas covered include quality of life and lifespan issues; population, health policy, and advocacy issues; health promotion and disease prevention; behavioral care in all types of settings; biological, psychological, and person factors in health behavior change; professional development and practice-related issues; and much more.
This encyclopedia is the first resource to which readers turn for factual, relevant, and comprehensive information to aid in delivering the highest quality services.
Inbunden, Engelska, 2010
3 600 kr
Skickas inom 5-8 vardagar
New Drug Development: Second Edition provides an overview of the design concepts and statistical practices involved in therapeutic drug development. This wide spectrum of activities begins with identifying a potentially useful drug candidate that can perhaps be used in the treatment or prevention of a condition of clinical concern, and ends with marketing approval being granted by one or more regulatory agencies. In between, it includes drug molecule optimization, nonclinical and clinical evaluations of the drug’s safety and efficacy profiles, and manufacturing considerations. The more inclusive term lifecycle drug development can be used to encompass the postmarketing surveillance that is conducted all the time that a drug is on the market and being prescribed to patients with the relevant clinical condition. Information gathered during this time can be used to modify the drug (for example, dose prescribed, formulation, and mode of administration) in terms of its safety and its effectiveness. The central focus of the first edition of this book is captured by its subtitle, 'Design, Methodology, and Analysis'. Optimum quality study design and experimental research methodology must be employed if the data collected—numerical representations of biological information—are to be of optimum quality. Optimum quality data facilitate optimum quality statistical analysis and interpretation of the results obtained, which in turn permit optimum quality decisions to be made: Rational decision making is predicated on appropriate research questions and optimum quality numerical information. The book took a non-computational approach to statistics, presenting instead a conceptual framework and providing readers with a sound working knowledge of the importance of design, methodology, and analysis. Not everyone needs to be an expert in statistical analysis, but it is very helpful for work (or aspire to work) in the pharmaceutical and biologics industries to be aware of the fundamental importance of a sound scientific and clinical approach to the planning, conduct, and analysis of clinical trials.
E-bok
PDF, Engelska, 20104 717 kr
Läs direkt efter köp
New Drug Development: Second Edition provides an overview of the design concepts and statistical practices involved in therapeutic drug development. This wide spectrum of activities begins with identifying a potentially useful drug candidate that can perhaps be used in the treatment or prevention of a condition of clinical concern, and ends with marketing approval being granted by one or more regulatory agencies. In between, it includes drug molecule optimization, nonclinical and clinical evaluations of the drug’s safety and efficacy profiles, and manufacturing considerations. The more inclusive term lifecycle drug development can be used to encompass the postmarketing surveillance that is conducted all the time that a drug is on the market and being prescribed to patients with the relevant clinical condition. Information gathered during this time can be used to modify the drug (for example, dose prescribed, formulation, and mode of administration) in terms of its safety and its effectiveness. The central focus of the first edition of this book is captured by its subtitle, ''Design, Methodology, and Analysis''. Optimum quality study design and experimental research methodology must be employed if the data collected—numerical representations of biological information—are to be of optimum quality. Optimum quality data facilitate optimum quality statistical analysis and interpretation of the results obtained, which in turn permit optimum quality decisions to be made: Rational decision making is predicated on appropriate research questions and optimum quality numerical information. The book took a non-computational approach to statistics, presenting instead a conceptual framework and providing readers with a sound working knowledge of the importance of design, methodology, and analysis. Not everyone needs to be an expert in statistical analysis, but it is very helpful for work (or aspire to work) in the pharmaceutical and biologics industries to be aware of the fundamental importance of a sound scientific and clinical approach to the planning, conduct, and analysis of clinical trials.
Häftad, Engelska, 2011
562 kr
Skickas inom 10-15 vardagar
This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.
E-bok
PDF, Engelska, 2011734 kr
Läs direkt efter köp
This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.
E-bok
PDF, Engelska, 20132 110 kr
Läs direkt efter köp
Leading researchers examine how behavior genetics provides crucial insights into genetic and environmental influences in the development of biobehavioral disorders. These influences are illustrated by using the examples of cardiovascular disease, obesity and eating disorders, alcohol use and abuse, and smoking behavior. Contributors discuss the relevance of molecular genetic approaches and twin and family designs to the complex field of behavior medicine research.
Häftad, Engelska, 2013
1 670 kr
Skickas inom 10-15 vardagar
Leading researchers examine how behavior genetics provides crucial insights into genetic and environmental influences in the development of biobehavioral disorders. These influences are illustrated by using the examples of cardiovascular disease, obesity and eating disorders, alcohol use and abuse, and smoking behavior. Contributors discuss the relevance of molecular genetic approaches and twin and family designs to the complex field of behavior medicine research.
E-bok
PDF, Engelska, 20131 459 kr
Läs direkt efter köp
This book is an articulate, concise, contemporary introduction to the study of important variables underlying cardiovascular reactivity. Its strength is in the combination of a scholarly but nonpedantic approach to cardiovascular psychophysiology and a solid understanding of be havioral medicine approaches to the study of hypertension. The topics covered are central to the study of relationships between behavior and cardiovascular reactivity; the list of suggested readings at the end of each chapter provides excellent guidance for more detailed study of specific issues. It has now been more than a dozen years since Plenum Press published Paul Obrist''s seminal monograph Cardiovascular Psycho physiology. The volume had a major impact in relating cardiovascular regulation to behaving individuals and in developing thoughtful hy potheses concerning such factors as they might pertain to hypertension. The impact of that work extended across scientific disciplines as well as aross continents. At the time the Obrist book was published, a young psychologist, J. Rick Turner, was completing his Ph. D. thesis in psychol ogy at the University of Birmingham, England, on heart rate reactions to psychological challenge. After continued collaboration for the next several years with his former Ph. D. mentor, Douglas Carroll, Turner joined the Obrist laboratory at the University of North Carolina. Al though Obrist unfortunately died during Turner''s tenure in the labora tory, collaboration continued with Kathleen Light and Andrew Sher wood. The enlightened legacy of the North Carolina laboratory can clearly be seen in this text.
Häftad, Engelska, 2013
1 116 kr
Skickas inom 10-15 vardagar
This book is an articulate, concise, contemporary introduction to the study of important variables underlying cardiovascular reactivity. It has now been more than a dozen years since Plenum Press published Paul Obrist's seminal monograph Cardiovascular Psycho physiology.
E-bok
PDF, Engelska, 20131 992 kr
Läs direkt efter köp
Demonstrating that the magnitude and pattern of cardiovascular response to stress varies markedly between individuals, this work discusses the mechanisms by which the cardiovascular system is mobilized during stress, the determinants of individual differences, and the pathophysiological processes by which responses to stress may lead to cardiovascular disease. Behavioral scientists from a variety of disciplines will find the work pertinent to their research.
Häftad, Engelska, 2013
1 576 kr
Skickas inom 10-15 vardagar
Demonstrating that the magnitude and pattern of cardiovascular response to stress varies markedly between individuals, this work discusses the mechanisms by which the cardiovascular system is mobilized during stress, the determinants of individual differences, and the pathophysiological processes by which responses to stress may lead to cardiovascular disease. Behavioral scientists from a variety of disciplines will find the work pertinent to their research.
Häftad, Engelska, 2014
3 600 kr
Skickas inom 5-8 vardagar
New Drug Development: Second Edition provides an overview of the design concepts and statistical practices involved in therapeutic drug development. This wide spectrum of activities begins with identifying a potentially useful drug candidate that can perhaps be used in the treatment or prevention of a condition of clinical concern, and ends with marketing approval being granted by one or more regulatory agencies. In between, it includes drug molecule optimization, nonclinical and clinical evaluations of the drug’s safety and efficacy profiles, and manufacturing considerations. The more inclusive term lifecycle drug development can be used to encompass the postmarketing surveillance that is conducted all the time that a drug is on the market and being prescribed to patients with the relevant clinical condition. Information gathered during this time can be used to modify the drug (for example, dose prescribed, formulation, and mode of administration) in terms of its safety and its effectiveness. The central focus of the first edition of this book is captured by its subtitle, 'Design, Methodology, and Analysis'. Optimum quality study design and experimental research methodology must be employed if the data collected—numerical representations of biological information—are to be of optimum quality. Optimum quality data facilitate optimum quality statistical analysis and interpretation of the results obtained, which in turn permit optimum quality decisions to be made: Rational decision making is predicated on appropriate research questions and optimum quality numerical information. The book took a non-computational approach to statistics, presenting instead a conceptual framework and providing readers with a sound working knowledge of the importance of design, methodology, and analysis. Not everyone needs to be an expert in statistical analysis, but it is very helpful for work (or aspire to work) in the pharmaceutical and biologics industries to be aware of the fundamental importance of a sound scientific and clinical approach to the planning, conduct, and analysis of clinical trials.
Inbunden, Engelska, 2016
1 116 kr
Skickas inom 10-15 vardagar
At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.“a resource that will likely serve as a standard for years to come” - Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180“I have no hesitation in recommending this book as a valuable reference source” - Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63
E-bok
Engelska, 2016978 kr
Läs direkt efter köp
At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.
Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.“a resource that will likely serve as a standard for years to come”
- Dr Jonathan Seltzer
Therapeutic Innovation & Regulatory Science, 2017;51(2):180
“I have no hesitation in recommending this book as a valuable reference source”
- Dr Rashmi Shah
Journal for Clinical Studies, 2017;9(1):62-63
Häftad, Engelska, 2018
783 kr
Skickas inom 10-15 vardagar
At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.“a resource that will likely serve as a standard for years to come” - Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180“I have no hesitation in recommending this book as a valuable reference source” - Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63
Häftad, Engelska, 2008
576 kr
Tillfälligt slut
This book is a self-contained introduction to Statistics, presented in the context of clinical trials and pharmaceutical drug development. It focuses on the statistical analyses most commonly used in drug development and is therefore an ideal introduction to pharmaceutical statistics. Instead of introducing a series of statistical techniques, the book's organizational structure follows the order in which numerical information and statistical analyses are used in trials and new drug development.All students taking classes in pharmaceutical sciences and clinical research need a solid knowledge and understanding of the nature, methods, application and importance of Statistics. They need to understand:why, and how data are collected in clinical trials; how these data are summarized and analyzed; what the results mean in the context of the clinical research question; and, how the results are communicated to regulatory agencies and to scientific and medical communities.This title therefore adopts a unique approach and concept in organization of the content. It begins with an introduction to statistical theory, analysis and interpretation.This is followed by a discussion of t-tests and confidence intervals. Readers are then taken through the whole process of new drug development (using one specific example throughout) that is meaningful in the context of their broader studies. Throughout this process, statistical techniques and analyses are introduced in the order in which they are employed during the process.The book's realistic scientific and progressive organization from pre-clinical trials to clinical pharmacology through clinical trials is novel, meaningful and educationally powerful. The book emphasises the importance of descriptive statistics as well as inferential statistics, something that is rarely done.Supplementary material is included for this text on the PharmPress website in the form of PowerPoint lecture notes on Statistics (based on content of this book) that can be downloaded by lecturers.